viral
respiratori
infect
increasingli
recogn
main
contributor
hospit
mortal
age
group
worldwid
appropri
manag
patient
viral
respiratori
ill
requir
rapid
accur
identif
etiolog
agent
infect
unfortun
identifi
specif
viral
respiratori
pathogen
infect
problemat
elus
sever
reason
wide
rang
potenti
viral
pathogen
caus
similar
clinic
manifest
insensit
convent
laboratori
diagnost
test
presenc
new
mutat
viral
pathogen
rapid
detect
identif
viral
pathogen
caus
respiratori
tract
infect
demonstr
significantli
decreas
durat
hospit
reduc
manag
cost
avoid
addit
laboratori
test
unnecessari
antibiot
use
addit
rapid
detect
identif
help
guid
specif
antivir
therapi
appropri
isol
precaut
major
caus
viral
respiratori
diseas
children
adult
influenza
viru
flu
b
parainfluenza
viru
type
respiratori
syncyti
viru
rsv
adenovirus
adv
enterovirus
env
howev
result
applic
novel
detect
techniqu
virus
ad
list
signific
viral
respiratori
pathogen
coronavirus
cov
human
metapneumoviru
hmpv
human
rhinovirus
hrhv
human
bocavirus
hbov
newli
discov
parvoviru
type
mimiviru
respiratori
polyomavirus
xenotrop
murin
leukemia
virusrel
viru
xmrv
emerg
pathogen
identifi
sinc
caus
pandem
fatal
respiratori
infect
includ
sever
acut
respiratori
syndrom
sar
cov
avian
influenza
virus
swine
influenza
virus
furthermor
clinic
signific
other
still
known
inde
virus
mention
associ
similar
atyp
clinic
present
infect
upper
lower
respiratori
tract
make
difficult
clinician
distinguish
caus
pathogen
without
laboratori
diagnosi
tradit
excel
specif
viru
isol
respiratori
secret
cultur
test
remain
gold
standard
laboratori
diagnosi
viral
respiratori
infect
viral
cultur
use
highli
febril
patient
ill
day
recov
viral
strain
use
character
antivir
suscept
test
howev
viral
cultur
technic
demand
rel
insensit
compar
serolog
test
pcr
time
consum
even
incorpor
shell
vial
cultur
techniqu
viral
pathogen
eg
hbov
cultur
cultiv
highli
contagi
viral
pathogen
eg
sar
cov
routin
diagnost
laboratori
danger
laboratori
staff
variou
rapid
antigen
test
mainstay
clinic
laboratori
diagnos
viral
respiratori
infect
sever
format
led
immunofluoresc
antibodi
assay
ifa
direct
fluoresc
antibodi
assay
dfa
enzym
immunoassay
eia
avail
detect
even
subtyp
main
respiratori
virus
eg
flu
rsv
within
short
time
kept
mind
falseneg
rapid
antigen
result
expect
interpret
exclud
possibl
infect
caus
test
viral
pathogen
low
sensit
rapid
antigen
test
usual
releg
pointofcar
test
influenza
defin
set
serologybas
procedur
primarili
surveil
epidemiolog
studi
wherea
applic
diagnosi
viral
respiratori
diseas
limit
singl
serum
sampl
detect
viralspecif
igg
use
diagnosi
instead
pair
acut
convalescentphas
sera
collect
least
day
apart
need
detect
fourfold
greater
increas
serum
antibodi
level
indic
recent
infect
technic
advanc
molecular
biolog
significantli
expand
improv
capabl
diagnost
microbiolog
nucleic
acid
amplif
test
led
polymeras
chain
reaction
pcr
develop
respiratori
virus
end
decad
today
emerg
use
routin
clinic
laboratori
prefer
method
viral
diagnost
test
either
adjunct
replac
anoth
method
realtim
technolog
abil
perform
multiplex
test
facilit
emerg
molecular
techniqu
found
nich
laboratori
diagnosi
viral
respiratori
tract
infect
provid
rapid
highli
sensit
tool
detect
identifi
causal
pathogen
also
allow
assess
impact
wider
array
potenti
pathogen
viral
respiratori
infect
previous
possibl
targetspecif
multiplex
approach
prove
feasibl
enhanc
broadspectrum
respiratori
viru
diagnosi
wide
rang
target
signal
amplif
nucleic
acid
amplif
method
could
appli
respiratori
viru
detect
target
amplif
techniqu
advantag
sensit
signal
amplif
latter
may
simpler
less
labori
high
throughput
review
focu
commerci
avail
molecular
assay
discuss
perform
characterist
requir
success
implement
molecular
method
routin
diagnosi
viral
respiratori
infect
despit
avail
vaccin
influenza
viru
remain
lead
caus
acut
respiratori
infect
outbreak
everi
year
pandem
follow
emerg
novel
viru
subtyp
new
combin
hemagglutinin
ha
neuraminidas
na
gene
rapid
antigen
assay
detect
influenza
commonli
avail
although
neg
result
use
assay
increas
significantli
increas
age
patient
realtim
pcr
cultur
necessari
avoid
falseneg
result
older
patient
molecular
method
detect
influenza
virus
describ
earli
variou
target
use
includ
matrix
ha
na
gene
first
commerci
avail
assay
hexaplex
assay
prodess
inc
waukesha
wi
analyt
sensit
copi
influenza
five
copi
influenza
b
set
standard
detect
influenza
virus
sinc
develop
food
drug
administr
fda
approv
multiplex
rtpcr
assay
proflu
prodess
inc
detect
influenza
influenza
b
rsv
accord
manufactur
clinic
sensit
specif
influenza
influenza
b
respect
anoth
fdaapprov
multiplex
panel
xtag
respiratori
viru
panel
rvp
luminex
molecular
diagnost
toronto
canada
capabl
detect
respiratori
virus
subtyp
includ
influenza
assay
use
multiplex
pcr
luminex
xmap
suspens
array
report
clinic
sensit
influenza
addit
fdaapprov
assay
sever
manufactur
molecular
assay
avail
analyt
specif
reagent
asr
research
use
ruo
kit
multicodeplx
rvp
eragen
bioscienc
inc
madison
wi
resplex
ii
panel
qiagen
inc
valencia
ca
perform
claim
report
similar
xtag
rvp
autom
solid
film
microarray
system
detect
identif
panel
respiratori
virus
commerci
avail
clinic
trial
includ
infin
analyz
autogenom
inc
carlsbad
ca
filmarray
idaho
technolog
inc
salt
lake
citi
ut
particular
multiplex
pcr
test
report
sentinel
appear
emerg
novel
genotyp
andor
subtyp
influenza
virus
avian
influenza
viru
swine
influenza
viru
fluplexid
devic
combin
multilocu
pcr
amplif
mass
spectrometri
detect
develop
ibi
bioscienc
carlsbad
ca
valid
clinic
trial
devic
cover
subtyp
varieti
flu
subtyp
mutant
high
sensit
specif
unpublish
observ
rsv
singl
import
respiratori
viral
pathogen
infant
young
children
import
pathogen
respiratori
diseas
elderli
highrisk
adult
rapid
antigen
assay
eia
format
use
mani
year
rsv
detect
good
specif
poor
sensit
specimen
neg
antigen
result
routin
retest
cultur
influenza
hexaplex
assay
first
commerci
avail
assay
rsv
detect
clinic
sensit
specif
mix
popul
adult
children
redesign
multiplex
rtpcr
format
proflu
receiv
fda
clearanc
anoth
fdaapprov
molecular
devic
xtag
rvp
luminex
cover
rsv
well
fdaclear
devic
much
higher
clinic
sensit
specif
rsv
detect
compar
convent
rapid
antigen
immunoassay
especi
immunocompromis
adult
ruo
asr
assay
commerci
avail
rsv
detect
rsva
b
subgroup
includ
multicodeplx
rvp
eragen
resplex
ii
qiagen
demonstr
multiplex
molecular
devic
sensit
method
detect
rsv
regardless
popul
test
moreov
specimen
low
viral
load
adult
immunocompromis
patient
like
antigen
neg
rtpcr
posit
human
parainfluenza
virus
contain
four
subtyp
piv
associ
distinct
clinic
syndrom
age
group
season
piv
relat
group
import
human
respiratori
pathogen
especi
young
children
piv
much
less
studi
piv
gener
appear
caus
less
sever
respiratori
ill
rel
common
respiratori
virus
piv
somewhat
neglect
laboratori
cultur
rel
insensit
current
diagnosi
depend
mainli
rapid
antigen
detect
dfa
number
multiplex
respiratori
viru
assay
includ
piv
target
fdaapprov
assay
cover
piv
xtag
rvp
luminex
clinic
sensit
piv
respect
multicodeplx
ruo
assay
eragen
report
sensit
wherea
resplex
ii
ruo
assay
qiagen
crossreact
piv
piv
proparaflu
assay
prodess
avail
ruo
kit
multicent
clinic
trial
way
fda
submiss
least
adv
demonstr
infect
human
group
six
speci
f
adenovirus
common
caus
selflimit
respiratori
ill
outbreak
immunocompet
children
us
militari
recruit
report
caus
sever
prolong
sometim
fatal
ill
immunocompromis
host
human
adenovirus
caus
respiratori
diseas
found
speci
b
c
e
convent
diagnost
method
respiratori
adenovirus
infect
includ
cultur
rapid
antigen
detect
dfa
molecular
method
provid
sensit
method
detect
adv
clinic
materi
although
valid
comparison
differ
method
perform
one
adv
molecular
assay
use
convent
pcr
amplif
follow
hybrid
probe
microtit
plate
avail
commerci
argen
sherley
ny
ruo
format
three
commerci
multiplex
pcr
assay
multicodeplx
assay
eragen
resplex
ii
assay
qiagen
xtag
rvp
assay
luminex
detect
adv
perform
larg
unknown
date
xtag
rvp
assay
fdaapprov
molecular
test
detect
adv
respiratori
specimen
clinic
sensit
sinc
discoveri
hmpv
establish
signific
respiratori
etiolog
agent
children
adult
sever
hmpv
infect
result
hospit
intens
care
unit
admiss
describ
elderli
adult
underli
condit
immunocompromis
patient
hmpv
infect
diagnos
use
varieti
approach
includ
serolog
viru
isol
antigen
nucleic
acid
detect
avail
commerci
molecular
assay
includ
xtag
rvp
assay
luminex
resplex
ii
qiagen
multicodeplx
rvp
eragen
pro
hmpv
real
time
assay
ruo
prodess
inc
seeplex
rv
detect
kit
seegen
inc
seoul
south
korea
xtag
rvp
assay
fdaapprov
commerci
multiplex
assay
hmpv
sensit
specif
prohmpv
assay
clinic
sensit
accord
manufactur
sensit
specif
resplex
ii
multicodeplx
assay
detect
hmpv
determin
report
multicodeplx
ruo
assay
much
sensit
resplex
ii
panel
ruo
assay
howev
report
suffer
low
number
posit
sampl
lack
compar
assay
human
rhinovirus
coronavirus
previous
consid
convent
virus
associ
upper
respiratori
infect
howev
recent
report
higherthanexpect
rate
respiratori
hospit
rhinovirus
consid
clinic
import
infecti
diseas
clinician
recent
report
caus
seriou
lower
respiratori
tract
infect
young
children
adult
immunocompromis
individu
although
rhinovirus
detect
viral
cultur
clinic
laboratori
provid
rhinoviru
diagnosi
recent
sever
inhous
develop
molecular
assay
show
sensit
rhinoviru
detect
use
nasba
use
rtpcr
four
recent
introduc
commerci
multiplex
resplex
ii
assay
qiagen
multicodeplx
rvp
assay
eragen
seeplex
rv
assay
seegen
xtag
rvp
assay
luminex
rhinoviru
target
howev
xtag
rvp
assay
approv
fda
rhinoviru
detect
sensit
specif
clinic
evalu
note
appear
rhinovirus
detect
use
molecular
method
posit
result
confirm
cultur
impli
sequenc
data
differ
rhinoviru
serotyp
current
circul
strain
need
five
coronavirus
sarscov
describ
caus
human
respiratori
diseas
cov
associ
upper
lower
respiratori
tract
infect
varieti
set
includ
nosocomi
infect
highrisk
immunocompromis
children
hospit
elderli
patient
sarscov
caus
agent
outbreak
sar
worldwid
found
circul
peopl
sinc
two
new
cov
speci
describ
respect
varieti
molecular
techniqu
includ
rtpcr
nasba
lamp
appli
detect
cov
howev
avail
commerci
assay
approv
fda
detect
cov
infect
xtag
rvp
assay
luminex
cover
five
cov
portion
detect
differenti
cov
fda
clear
multiplex
pcrbase
devic
includ
multicodeplx
ruo
assay
eragen
resplex
ii
assay
qiagen
cover
cov
clinic
sensit
two
assay
await
investig
adequ
number
posit
specimen
human
bocaviru
new
viru
discov
use
nonspecif
largescal
molecular
viral
screen
techniqu
report
two
genotyp
hbov
circul
worldwid
sinc
first
public
numer
studi
report
hbov
preval
rang
respiratori
tract
specimen
patient
acut
respiratori
symptom
bocavirus
yet
isol
cell
cultur
hbov
infect
diagnos
exclus
use
molecular
method
time
write
fdaapprov
commerci
test
detect
hbov
version
resplex
ii
assay
qiagen
xtag
rvp
assay
luminex
cover
hbov
perform
await
complet
valid
analyt
diagnost
sensit
specif
hbov
assay
determin
clinic
relev
posit
hbov
result
merit
investig
import
viral
pathogen
eg
influenza
virus
rsv
mani
report
feasibl
studi
confirm
molecular
test
improv
sensit
detect
potenti
pathogen
lower
respiratori
tract
specimen
well
respiratori
swab
shorten
test
turnaround
time
therebi
improv
patient
care
molecular
assay
use
mainli
supplement
rapid
antigen
test
cultur
viral
pathogen
eg
parainfluenza
virus
adenoviru
enterovirus
molecular
assay
gradual
implement
mainstay
molecular
method
ensur
appropri
earli
manag
use
infect
prevent
control
procedur
vulner
individu
well
differenti
design
serotyp
epidemiolog
studi
newli
discov
respiratori
viral
pathogen
eg
hmpv
rhinovirus
coronavirus
molecular
assay
becom
exclus
tool
diagnost
algorithm
molecular
techniqu
also
result
discoveri
novel
respiratori
virus
human
bocavirus
respiratori
polyomavirus
xmrv
although
clinic
relev
need
investig
molecular
techniqu
design
monoplex
one
target
one
reaction
multiplex
multipl
target
one
reaction
format
recent
avail
multiplex
revers
devic
led
identif
viral
respiratori
coinfect
previous
recogn
studi
report
multipl
virus
detect
use
molecular
method
mani
institut
outbreak
viral
respiratori
diseas
commerci
avail
devic
includ
resplex
ii
qiagen
masstag
pcr
assay
center
infect
immun
columbia
univers
new
york
ny
respifind
assay
pathofind
maastricht
area
netherland
filmarray
idaho
technolog
salt
lake
citi
ut
sever
userdevelop
assay
cover
common
respiratori
viral
bacteri
pathogen
one
reaction
report
coinfect
medic
relev
effect
treatment
sever
respiratori
tract
infect
increasingli
requir
diagnosi
involv
pathogen
oppos
singlepathogen
report
howev
one
studi
netherland
indic
implement
multipl
molecular
assay
etiolog
diagnosi
lower
respiratori
tract
infect
increas
diagnost
yield
consider
yet
reduc
antibiot
use
cost
welldesign
outcom
studi
need
demonstr
clinic
relev
cost
effect
simultan
multipathogen
detect
identif
strategi
respiratori
viral
coinfect
interpret
report
may
need
assist
clinician
assess
mix
infect
distinct
advantag
molecular
techniqu
convent
method
abil
quantifi
viral
pathogen
although
qualit
molecular
test
use
diagnosi
viral
load
chang
respiratori
specimen
use
indic
test
cure
therapi
monitor
implement
realtim
technolog
rapid
accur
viral
load
quantif
molecular
assay
possibl
prove
use
clinic
set
realtim
pcr
assay
report
quantit
assess
viral
load
children
natur
infect
rsv
multiplex
typespecif
realtim
pcr
assay
report
detect
quantif
respiratori
adenovirus
quantit
realtim
pcr
assay
use
assess
influenza
viru
infect
includ
pandem
viru
correl
establish
viral
load
clinic
sever
durat
diseas
quantif
viral
load
may
help
clinician
predict
diseas
progress
interpret
clinic
relev
multipl
viral
pathogen
detect
sampl
monitor
efficaci
antivir
therapi
viral
load
data
provid
import
inform
regard
virushost
interact
use
predict
diseas
sever
transmiss
viral
respiratori
infect
quantit
molecular
assay
make
possibl
promptli
establish
correl
viral
load
profil
clinic
characterist
viral
respiratori
infect
would
provid
import
knowledg
clinic
manag
term
antivir
therapi
infect
control
measur
support
sever
recent
publish
studi
pandem
influenza
viru
virolog
profil
determin
quantit
rtpcr
suggest
prolong
viral
shed
young
children
higher
viral
load
stool
implic
formul
clinic
manag
polici
infect
control
measur
also
report
oral
oseltamivir
suppress
viral
load
effect
shorten
durat
viral
shed
given
earli
mild
case
pandem
infect
besid
rapid
detect
pandem
variant
distinguish
strain
circul
epidem
strain
identif
antiviralresist
variant
equal
import
pandem
surveil
patient
manag
rapid
detect
oseltamivir
resist
sever
pandem
infect
essenti
patient
receiv
maximum
therapeut
benefit
use
clinician
allow
chang
effect
treatment
much
earlier
stage
resist
found
recent
studi
report
use
novel
molecular
method
screen
presenc
resist
mutat
neuraminidas
gene
addit
accur
detect
oseltamivirresist
allel
sampl
collect
multipl
time
point
even
show
switch
wildtyp
oseltamivirsensit
h
oseltamivirresist
popul
day
treatment
light
emerg
resist
close
monitor
understand
natur
dynam
resist
mutat
newli
emerg
strain
prioriti
recent
pandem
respiratori
viral
diseas
outbreak
institut
present
signific
challeng
infect
control
epidemiolog
monitor
serolog
test
still
remain
use
epidemiolog
monitor
wherea
viral
cultur
permit
full
identif
character
novel
strain
emerg
virus
well
determin
antivir
phenotyp
suscept
enhanc
sensit
specif
molecular
method
result
convent
method
becom
secondari
tier
triag
diagnost
option
investig
outbreak
epidemiolog
studi
molecular
method
also
provid
much
shorter
test
turnaround
time
accur
result
vital
time
effect
intervent
outbreak
pandem
viral
respiratori
infect
molecular
method
increasingli
use
molecular
epidemiolog
studi
predomin
etiolog
agent
influenza
viru
rsv
season
epidem
studi
demonstr
applic
molecular
method
provid
crucial
epidemiolog
data
also
time
accur
diagnosi
outbreak
allow
earli
symptomat
treatment
ration
use
antibiot
improv
infect
control
epidem
recent
studi
report
support
use
molecular
assay
implement
molecular
monitor
system
endem
epidem
viral
respiratori
infect
institut
outbreak
multitarget
molecular
assay
becom
costeffect
increas
cost
test
offset
reduct
patient
care
cost
due
earlier
diagnost
result
provid
molecular
method
econom
advantag
even
obviou
institut
outbreak
pandem
viral
respiratori
infect
timetoresult
import
prevent
spread
diseas
howev
welldefin
outcom
studi
still
need
determin
costeffect
rapid
molecular
assay
nucleic
acidtarget
molecular
techniqu
enhanc
diagnost
sensit
specif
shorten
test
turnaround
time
provid
automat
highthroughput
process
identif
viral
pathogen
caus
respiratori
tract
infect
inhous
commerci
avail
molecular
method
increasingli
use
detect
identifi
common
respiratori
virus
well
recent
identifi
pathogen
techniqu
advanc
panel
viral
pathogen
qualit
quantit
detect
singl
reaction
significantli
enhanc
diagnost
efficaci
yield
implement
molecular
test
diagnosi
respiratori
viral
infect
limit
technic
complex
cost
lack
proper
valid
standard
assay
perform
characterist
limit
molecular
test
must
clearli
understood
laboratori
personnel
clinician
ensur
proper
util
interpret
prompt
exchang
relev
inform
clinician
laboratori
essenti
molecular
diagnosi
viral
respiratori
infect
moreov
interpret
report
may
play
role
mix
infect
occur
frequent
